GAMMAGARD LIQUID SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

IMMUNOGLOBULIN (HUMAN)

제공처:

TAKEDA CANADA INC

ATC 코드:

J06BA02

INN (International Name):

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASC. ADM.

복용량:

10%

약제 형태:

SOLUTION

구성:

IMMUNOGLOBULIN (HUMAN) 10%

관리 경로:

INTRAVENOUS

패키지 단위:

10/25/50/100/200/300ML

처방전 유형:

Schedule D

치료 영역:

SERUMS

제품 요약:

Active ingredient group (AIG) number: 0106267005; AHFS:

승인 상태:

APPROVED

승인 날짜:

2018-05-04

제품 특성 요약

_ _
_ _
_Page 1 of 56_
PRODUCT MONOGRAPH
GAMMAGARD LIQUID
®
Immunoglobulin
Intravenous (Human), [IGIV] 10%
Solution
for infusion and 1 g/10 mL, 2.5 g/25 mL, 5 g/50 mL, 10 g/100 mL, 20
g/200 mL,
30 g/300mL
Pharmacopeial
Replacement Therapy for Immunodeficiencies
Takeda Canada Inc.
22 Adelaide Street West, Suite 3800
Toronto Ontario M5H 4E3
Submission
Control No: 256703
Date of Initial Approval:
April 12, 2006
Date of Revision:
November 26, 2021
GAMMAGARD
®
and GAMMAGARD LIQUID
®
are registered trademarks of Baxalta
Incorporated. Takeda
TM
and the Takeda Logo
®
are trademarks of Takeda Pharmaceutical
Company Limited, used under license.
_ _
_ _
_Page 2 of 56_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................... 3
SUMMARY PRODUCT INFORMATION
................................................................... 3
DESCRIPTION
...........................................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................
4
CONTRAINDICATIONS
............................................................................................
5
WARNINGS AND PRECAUTIONS
............................................................................
6
ADVERSE
REACTIONS............................................................................................11
DRUG INTERACTIONS
............................................................................................15
DOSAGE AND ADMINISTRATION
.........................................................................16
OVERDOSAGE
.........................................................................................................18
ACTION AND CLINICAL
PHARMACOLOGY.........................................................18
STORAGE AND STABILITY
....................................................................................21
SPECIAL HANDLING INSTRUCTIONS
...............................................